TickerFacts.

TG Therapeutics, Inc. (TGTX): EBITDA

Operating income plus depreciation and amortization for the same annual period and currency, computed by TickerFacts from the filed figures. Not the company's adjusted EBITDA; a year without both inputs is left out.

Restated years: each year's figure is from the latest filing that reports it. The company later restated the year ended 2022-12-31 (for example after a spin-off or a discontinued operation), while the year before it was last reported on the old basis. Changes across those points are marked n/c (not comparable), and growth rates are not computed across them.

$123.38M
Year ended 2025-12-31
$136.45M
Trailing 12 months to 2026-06-30
2021-12-31: -$344.49M2022-12-31: -$218.01M2023-12-31: $20.84M2024-12-31: $42.00M2025-12-31: $123.38M$123.38M
2021-12-31 EBITDA (USD) 2025-12-31
Period endedEBITDAChange YoYSource filing
2025-12-31$123.38M+193.8%2026-02-27, From 2025-01-01
2024-12-31$42.00M+101.5%2026-02-27, From 2024-01-01
2023-12-31$20.84Mn/m2026-02-27, From 2023-01-01
2022-12-31-$218.01Mn/c2025-03-03, From 2022-01-01
2021-12-31-$344.49Mn/a2024-02-29, From 2021-01-01

EBITDA at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedEBITDAChange YoY
TG Therapeutics, Inc. (TGTX)2025-12-31$123.38M+193.8%
Opko Health, Inc. (OPK)2025-12-31-$25.78Mn/m
Ultragenyx Pharmaceutical Inc. (RARE)2025-12-31-$500.00Mn/m
Organogenesis Holdings Inc. (ORGO)2025-12-31$59.97M+386.0%
Kiniksa Pharmaceuticals International, plc (KNSA)2025-12-31$78.78Mn/m
HUTCHMED (China) Ltd (HCM)2025-12-31-$25.85Mn/m
Supernus Pharmaceuticals, Inc. (SUPN)2025-12-31$29.28M-81.9%
Pacira BioSciences, Inc. (PCRX)2025-12-31$110.21Mn/m
Mirum Pharmaceuticals, Inc. (MIRM)2025-12-31$2.11Mn/m

Compare TGTX, OPK, RARE, ORGO side by side · Screen every company in Pharmaceutical Preparations ↗